GlassScriptPhysician profile
Kory P Cummings
NPI 1083279921
$1,482.81
in general payments reported to CMS, 2019-2025
25 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.42 · 2020: $21.10 · 2021: $256 · 2022: $150 · 2023: $389 · 2024: $285 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $305.38 | 2023-2024 | Da Vinci Surgical System |
| Olympus America INC. | $201.70 | 2023-2024 | Spiration Valve System |
| Astrazeneca Pharmaceuticals LP | $106.16 | 2023-2025 | Airsupra, Tezspire, Fasenra |
| Kci USA, INC. | $93.90 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $85.79 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $83.54 | 2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.10 | 2019-2025 | Jascayd, Ofev |
| E.R. Squibb & Sons, L.L.C. | $65.48 | 2021-2022 | |
| Insmed, INC. | $60.26 | 2022-2025 | Brinsupri, Arikayce |
| Novartis Pharmaceuticals Corporation | $53.99 | 2019-2022 | |
| Pfizer INC. | $46.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.40 | 2024-2025 | Winrevair |
| Novo Nordisk INC | $27.63 | 2022 | |
| Amgen INC. | $27.25 | 2023 | Tezspire |
| Abiomed | $24.47 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $23.61 | 2021 | |
| Viatris Specialty LLC | $23.45 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $21.12 | 2025 | Inspire |
| Ibsa Pharma INC. | $21.10 | 2020 | |
| Integra Lifesciences Corporation | $21.07 | 2021 | |
| Viz.Ai, INC. | $20.47 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2025 | Glassia |
| Tandem Diabetes Care, INC. | $14.05 | 2019 | |
| Abbvie INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kory Cummings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.